OxfordBiomedica |

Loading...

Pipeline

We are working on several internal product candidates and have interests in an expanding range of partner programmes

Bioprocessing

Our bioprocessing expertise and facilities support both our own and our partners’ product development

Press releases

Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director

15 July 2021

Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine

18 May 2021

Oxford Biomedica 2020 Annual Report and Accounts & AGM Notification

27 April 2021

Preliminary results for the year ended 31 December 2020

15 April 2021

Platform

Our lentiviral vector delivery system, LentiVector^®, is enabling our customers to bring next generation treatments for serious diseases to market.

Latest annual report

Sign up for email alertsGo